Phase II Trial With Safety Run-in of the Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2018
At a glance
- Drugs Anetumab ravtansine (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2017 Planned End Date changed from 27 Apr 2020 to 26 Apr 2021.
- 21 Jun 2017 Planned primary completion date changed from 29 Apr 2019 to 27 Apr 2020.
- 31 May 2017 Status changed from not yet recruiting to recruiting.